ARBK vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 15, 2026

ARBK

51.8
AI Score
VS
HIVE Wins

HIVE

54.6
AI Score

Investment Advisor Scores

ARBK

52score
Recommendation
HOLD

HIVE

55score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric ARBK HIVE Winner
Forward P/E 100 62.8931 HIVE
PEG Ratio 0 0 Tie
Revenue Growth -74.7% 130.5% HIVE
Earnings Growth -94.0% -99.9% ARBK
Tradestie Score 51.8/100 54.6/100 HIVE
Profit Margin 32.8% -49.9% ARBK
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

ARBK 1M: -12.8% · 3M: -18.7% HIVE 1M: -15.5% · 3M: -1.0%

Current Technical Phase

ARBK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 39

RSI (14): 39.0 · Price: $2.88

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.8%), weak momentum, RSI 43

RSI (14): 43.4 · Price: $2.84

Fundamentals Snapshot

Metric ARBK HIVE
Market Cap
Forward P/E 100.0 -5.6
Trailing P/E 0.6
Revenue (TTM)
Revenue Growth -0.7% 1.3%
Gross Margin 0.2% 0.4%
Operating Margin -3.9% -0.8%
EPS 4.88 -0.64
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.